Psychedelic-assisted therapy: Treatment outcomes, therapeutic process, and ethical delivery

Write your awesome label here.
Join today
  • Virtual Webinar
  • February 19, 2027 @1:00-2:00pm EST
  • 1 Ethics CE Credit

Approved by the American and Canadian Psychological Associations

Course overview
Psychedelic-assisted therapy is a combined psychotherapeutic and pharmacologic intervention that involves administering a psychedelic agent (such as MDMA, psilocybin, or LSD) alongside structured psychotherapy or psychological support. Emerging evidence suggests potential benefits for several mental health concerns, including major depressive disorder, post-traumatic stress disorder, and cancer-related distress.

This presentation will describe the core elements of psychedelic-assisted therapy and outline how the approach differs from standard pharmacological treatment and conventional psychotherapy.

Discount coupons available for students with valid ID.

Please email education@nelliehealth.com for verification and coupon code.

  In this webinar we    will:

Practical approach

Review results from clinical trials completed over the past decade, with an emphasis on treatment outcomes, safety considerations, and key methodological limitations. 

Globally oriented

Discuss research aimed at understanding how psychedelic-assisted therapy leads to change and the role of psychotherapy within these interventions. 

For your career

Learn best practices and ethical considerations relevant to the delivery of psychedelic-assisted therapy and clinicians who encounter patients receiving or seeking psychedelic-assisted therapy.

Dr. Richard Zeifman

Richard Zeifman, Ph.D. is an Assistant Professor (Department of Psychology) and Director of the Psychedelic-Assisted Therapy (PATH) Lab at The New School for Social Research. He is also an Adjunct Assistant Professor (Department of Psychiatry) at the NYU Grossman School of Medicine and an Honorary Lecturer (Department of Brain Sciences) at Imperial College London. Richard completed his Ph.D. in Clinical Psychology at the Toronto Metropolitan University, clinical internship at the Centre for Addiction and Mental Health (CAMH), and postdoctoral fellowship at the NYU Grossman School of Medicine. Richard's research focuses on examining the safety, efficacy, and mechanisms of change underlying psychedelic therapy. He uses multi-method approaches and serves as a co-investigator on clinical trials of psychedelic therapy for the treatment of psychiatric disorders, including major depressive disorder and posttraumatic stress disorder (PTSD). He is a licensed clinical psychologist in Ontario and New York and a therapist on psilocybin and MDMA-assisted therapy trials.

Conflict of Interest Disclosure
Dr. Zeifman has served as a consultant to Beckley Clinical.

ACA/ADA Accommodations
If you require accommodations on the basis of disability, 
please contact education@nelliehealth.com

Please Download

For all Continuing Education Information on Psychedelic-assisted therapy: Treatment outcomes, therapeutic process, and ethical delivery, please click the link below to download.